← Eichor
Study identifier: NCT07531329 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer

Condition: Treatment-naive Prostate Cancer · Suspected Prostate Cancer · Molecular Imaging  ·  Sponsor: Xijing Hospital

PhaseN/A
Planned participants1000
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in patients with suspected newly diagnosed prostate cancer. Each patient serves as their own control, with diagnostic performance compared between standard (60-minute) and delayed (2-3 hour) acquisitions. Background PSMA PET has transformed prostate cancer imaging, with emerging evidence suggesting delayed acquisition may further improve diagnostic accuracy by increasing tumor-to-background ratio. Recent studies demonstrate that delayed imaging significantly reduces equivocal findings and enhances detection of clinically significant prostate cancer. Need While standard PSMA PET is well-validated, prospective multicenter data specifically evaluating the incremental diagnostic value of delayed imaging for clinically significant prostate cancer in treatment-naïve patients are lacking. This study addresses this gap by systematically comparing standard and delayed imaging in a large, well-defined cohort. Primary Outcome The primary outcome is to compare the area under the curve (AUC) of delayed SUVmax versus standard SUVmax for detecting clinically significant prostate cancer (csPCa), and to determine whether delayed imaging is superior to standard imaging. Secondary Outcomes 1. Optimal diagnostic thresholds for delayed imaging 1. Determine the optima…

This description comes directly from the study's public registry record.

Talk to the study team

Jianhua Jiao, MD.  ·  +86 18700919857  ·  1531769428@qq.com

Always discuss trial participation with your own doctor first.

Locations (9)

The First Hospital of Lanzhou UniversityLanzhou, Gansu, ChinaRecruiting
General Hospital of Ningxia Medical UniversityYinchuan, Ningxia, ChinaRecruiting
Qinghai University Affiliated HospitalXining, Qinghai, ChinaRecruiting
Weinan Central HospitaWeinan, Shaanxi, ChinaRecruiting
Xijing 986 HospitalXi'an, Shaanxi, ChinaRecruiting
Xijing HospitalXi'an, Shaanxi, ChinaRecruiting
Shaanxi Provincial People's HospitalXi'an, Shaanxi, ChinaRecruiting
The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, Shaanxi, ChinaRecruiting
Affiliated Hospital of Yan'an UniversityYan’an, Shaanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07531329